D(3) dopamine receptor
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats D(3) dopamine receptor as ChEMBL target CHEMBL3138, mapped to UniProt P19020. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why D(3) dopamine receptor matters
D(3) dopamine receptor is reviewed as D(3) dopamine receptor (UniProt P19020); the current evidence base includes 21 approved drugs, 842 compounds, and 144 assays, with lead potency reaching pChEMBL 10.4.
D(3) dopamine receptor Sequence length is 446 aa.
Review this target as D(3) dopamine receptor, mapped to UniProt P19020. Sequence length is 446 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 21 approved drugs, 842 compounds, and 144 assays for this target. The dominant activity type is KI. CHEMBL52588 is the current potency anchor at pChEMBL 10.4.
Use CHEMBL52588 as the tractability anchor when discussing potency (pChEMBL 10.4).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why D(3) dopamine receptor matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P19020, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL52588
|
10.4 | Ki | — |
|
|
No preferred name
CHEMBL54866
|
10.4 | Ki | — |
|
|
No preferred name
CHEMBL492664
|
10.4 | Ki | — |
|
|
No preferred name
CHEMBL120851
|
10.3 | Kd | — |
|
|
No preferred name
CHEMBL20734
|
10.2 | Kd | Clinical |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
CARIPRAZINE HYDROCHLORIDE
CHEMBL2024517
|
2015 |
|
|
VILAZODONE
CHEMBL439849
|
2011 |
|
|
ARIPIPRAZOLE
CHEMBL1112
|
2002 |
|
|
APOMORPHINE
CHEMBL53
|
2001 |
|
|
APOMORPHINE HYDROCHLORIDE
CHEMBL3187985
|
2001 |
|
|
PRAMIPEXOLE
CHEMBL301265
|
1997 |
|
|
ROPINIROLE
CHEMBL589
|
1997 |
|
|
OLANZAPINE
CHEMBL715
|
1996 |
|
|
RISPERIDONE
CHEMBL85
|
1993 |
|
|
CLOZAPINE
CHEMBL42
|
1989 |
|
|
PERGOLIDE
CHEMBL531
|
1988 |
|
|
METOCLOPRAMIDE
CHEMBL86
|
1979 |
|
|
DOPAMINE
CHEMBL59
|
1974 |
|
|
HALOPERIDOL
CHEMBL54
|
1967 |